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KAJIAN TERAZOSIN UNTUK RAWATAN SIMPTOM-SIMPTOM SALUR 
KENCING BAWAH WANITA 
 
ABSTRAK 
 
Simptom salur kencing bawah wanita adalah satu keadaan biasa yang mempengaruhi 
wanita dalam semua lingkungan umur dan ia memberi kesan yang buruk terhadap 
kualiti kehidupan. Walau bagaimanapun, tiada definisi piawai ataupun panduan untuk 
diagnosis dan rawatan masalah ini. Keputusan rawatan masih tidak memuaskan. Oleh 
itu, kajian ini dijalankan untuk menentukan keberkesanan klinikal dan keselamatan 
terazosin dalam rawatan pesakit simptom salur kencing bawah wanita. 
 
Bahagian pertama kajian ini adalah untuk mengesahkan kegunaan Skor Simptom 
Prostat Antarabangsa dan Soal Selidik Kesihatan King’s dalam kalangan pesakit 
simptom salur kencing bawah wanita. Adalah didapati bahawa kedua-dua Skor 
Simptom Prostat Antarabangsa dan Soal Selidik Kesihatan King’s adalah sah, dapat 
dipercayai dan bergerak balas terhadap perubahan dalam kalangan pesakit simptom 
salur kencing bawah wanita dan dengan itu ia sesuai digunakan sebagai ukuran dalam 
kajian rawatan terazosin. 
 
Daripada kajian prevalens yang dijalankan, kadar prevalens ialah 19% daripada 2732 
wanita berumur >19 tahun yang disoal selidik di dua buah negeri di kawasan utara 
Semenanjung Malaysia (Penang dan Kedah) dari bulan Januari hingga Ogos, 2004. 
Lebih daripada 50% pesakit simptom salur kencing bawah wanita berasa tidak gembira 
dengan pembuangan air kecil mereka. Analisis terhadap tingkah laku mencari rawatan 
bagi pesakit simptom salur kencing bawah wanita mendedahkan bahawa sebab utama 
pesakit simptom salur kencing bawah wanita menangguh mencari rawatan disebabkan 
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mereka kekurangan pengetahuan mengenai perkembangan penyakit dan pilihan 
rawatan yang sedia ada. 
 
Analisis faktor risiko pesakit simptom salur kencing bawah wanita menunjukkan 
bahawa wanita yang mempunyai risiko yang lebih tinggi untuk mendapat simptom salur 
kencing bawah wanita (didefinisikan sebagai nisbah ganjil ≥2) termasuk mereka yang 
berumur ≥50, pariti ≥4, buta huruf, selepas menopos dan mempunyai ≥1 penyakit 
kronik. Oleh itu, pihak pemberi perkhidmatan kesihatan umum patut melaksanakan 
strategi yang mensasar kepada golongan ini untuk mewujudkan kesedaran di kalangan 
mereka. 
 
Seterusnya, adalah didapati bahawa tingkah laku mencari rawatan untuk pesakit 
simptom salur kencing bawah wanita dari kedua-dua populasi umum dan persekitaran 
klinikal adalah dikaitkan dengan kesan terhadap kualiti kehidupan dan tidak berkaitan 
dengan keterukan simptom yang dikategorikan dengan jumlah Skor Simptom Prostat 
Antarabangsa. 
 
Dalam bahagian terakhir kajian ini, seratus pesakit simptom salur kencing bawah 
wanita telah diberi terazosin atau placebo secara rawak selama 14 minggu dalam 
kajian prospektif ini. Terazosin didapati berjaya mengurangkan secara signifikan 
jumlah Skor Simptom Prostat Antarabangsa dan Indeks Kualiti Kehidupan Skor 
Simptom Prostat Antarabangsa, semua domain kualiti kehidupan Soal Selidik 
Kesihatan King’s (kecuali domain Ukuran Keterukan) jika dibandingkan dengan 
placebo di kalangan pesakit simptom salur kencing bawah wanita. Tambahan pula, 
tidak terdapat perbezaan statistik secara signifikan dalam kejadian kesan sampingan di 
antara kumpulan yang menerima terazosin atau placebo. Oleh itu, terazosin didapati 
berkesan dan selamat dalam merawat pesakit simptom salur kencing bawah wanita. 
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STUDY OF TERAZOSIN IN THE TREATMENT OF FEMALE LOWER 
URINARY TRACT SYMPTOMS 
 
ABSTRACT 
 
Female Lower Urinary Tract Symptoms (FLUTS) is a common condition affecting 
women of all ages and it adversely affects quality of life (QOL). However, there are 
neither standard definitions nor guidelines for its diagnosis and treatment. Treatment 
outcomes have been unsatisfactory. Hence, this study was conducted to determine the 
clinical efficacy and safety of terazosin in treating patients with FLUTS. 
 
The first part of the study was to validate the International Prostate Symptom Score 
(IPSS) and King’s Health Questionnaire (KHQ) in patients with FLUTS. It was found 
that both the IPSS and KHQ were valid, reliable and responsive to changes in patients 
with FLUTS and hence suitable to be used as outcome measures in the terazosin 
treatment study. 
 
From the prevalence study conducted, there was a prevalence rate of 19% from 2732 
females aged >19 years surveyed within two states in Northern Peninsular Malaysia 
(Penang and Kedah) from Jan-Aug, 2004. More than 50% of patients with FLUTS felt 
unhappy with their urinary conditions. Analysis of treatment seeking behaviour of 
patients with FLUTS revealed the major underlying reason for those deferring 
treatment was that they lack of knowledge of the disease progress and treatment 
options available. 
 
Analysis of the risk factors for patients with FLUTS showed that females who are at 
higher risk to have FLUTS (defined as odds ratio (OR) ≥2) included those with age ≥50, 
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parity ≥4, illiterate, post menopausal and have ≥1 concomitant chronic medical illness. 
Therefore, public health service providers should implement strategies targeted at 
these groups to create awareness among them. 
 
Furthermore, it was found that treatment seeking behaviour of patients with FLUTS 
from both general population and clinical setting was associated with QOL impact of 
FLUTS and not symptoms severity categorised using total IPSS.  
 
In the final part of the study, 100 patients with FLUTS were randomised to receive 
either terazosin or placebo for 14 weeks in the prospective, double-blind, placebo-
controlled study. Terazosin was found to show a statistically significant reduction in 
total IPSS and IPSS QOL assessment index, all domains of QOL of the KHQ (except 
domain of severity measures) as compared to placebo in patients with FLUTS. 
Moreover, there was no statistically significant difference between treatment groups in 
the occurrence of adverse events. As such, terazosin was found to be effective and 
safe in treating patients with FLUTS. 
 
1
CHAPTER 1 
INTRODUCTION TO FEMALE LOWER URINARY TRACT SYMPTOMS 
(FLUTS) 
 
1.1 INTRODUCTION 
Results of population surveys have shown that the prevalence of female lower urinary 
tract symptoms (FLUTS) was high ranging from 12% to 39% (Pinnock & Marshall, 
1997; Yu et al., 1998; Moller et al., 2000a; Boyle et al., 2003a; Low et al., 2006). 
Prevalence of specific symptoms such as urgency was found to as high as 61% and 
incomplete emptying was 43% (Swithinbank & Abrams, 2000). Patients with FLUTS 
were associated with a lower overall health status (Yu et al., 1998; Boyle et al., 2003b), 
with patients restricting activities, for example only going to places where there are 
known toilet facilities (so-called ‘toilet mapping’), and having to carry extra underwear 
and pads (Freeman & Adekanmi, 2005). Many patients even limited drinking in an 
attempt to prevent symptoms (Freeman & Adekanmi, 2005). Patients with FLUTS 
experienced both financial and intangible loss such as personal and emotional distress 
(Kelleher, 2002). Most research on lower urinary tract function have focused on the 
filling phase of the micturation cycle, or the study of urinary incontinence (Groutz et al., 
1999), but not FLUTS. The pathophysiological mechanisms of female voiding phase 
dysfunction are poorly understood, and there are neither standard definitions nor 
guidelines for its diagnosis and treatment (Groutz & Blaivas, 2002). At present, the 
management of FLUTS includes excluding pathology and implementing behaviour 
changes such as caffeine reduction, bladder and pelvic floor training, as well as 
antimuscarinic drug therapy. The aetiology in most cases is unknown, and treatment 
outcomes have been unsatisfactory (Freeman & Adekanmi, 2005). 
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1.2 DEFINITION 
Symptoms are the subjective indicators of a disease. Symptoms or change in health 
status as perceived by the patient, care provider or partner may lead him/her to seek 
help from health care professionals. Descriptions of symptoms are either volunteered 
by, or elicited from the individual or even the individual’s caregiver. Such descriptions 
are usually qualitative in nature (Abrams et al., 2002). 
 
Lower urinary tract symptoms (LUTS) is a term that describes symptoms related to 
both the storage and emptying phases of the micturation cycle (Chaikin & Blaivas, 
2001). The Standardisation Sub-committee of the International Continence Society 
(ICS) on the Standardisation of Terminology of Lower Urinary Tract Function has 
divided LUTS into three groups, namely, storage, voiding and post micturation 
symptoms. LUTS are defined from the individual’s perspective. In general, LUTS 
cannot be used to make a definitive diagnosis. LUTS can also indicate pathologies 
other than lower urinary tract dysfunction, such as urinary tract infections (UTI) 
(Abrams et al., 2002).  
 
1.2.1 STORAGE SYMPTOMS 
The Standardisation Sub-committee of the ICS on the Standardisation of Terminology 
of Lower Urinary Tract Function defines storage symptoms as symptoms experienced 
during the storage phase of the bladder. They include the following (Abrams et al., 
2002): 
 
a) Increased daytime frequency 
Increased daytime frequency is the complaint by the patient who considers that he/she 
voids too often by day. 
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b) Nocturia 
Nocturia is defined as waking up at night one or more times to void. 
 
c) Urgency 
Urgency is a sudden compelling desire to pass urine, which is difficult to defer. 
 
d) Urinary incontinence 
Urinary incontinence is the complaint of any involuntary leakage of urine. In each 
specific circumstance, urinary incontinence should be further described by specifying 
relevant factors such as type, frequency, severity, precipitating factors, social impact, 
effect on hygiene and quality of life (QOL), the measures used to contain the leakage, 
and whether or not the individual seeks or desires help because of urinary 
incontinence. 
 
e) Stress urinary incontinence (SUI) 
SUI is involuntary leakage on effort or exertion, or on sneezing or coughing. 
 
f) Urge urinary incontinence 
Urge urinary incontinence is involuntary leakage accompanied by or immediately 
preceded by urgency. 
 
g) Mixed urinary incontinence 
Mixed urinary incontinence is involuntary leakage associated with urgency and also 
with exertion, effort, sneezing or coughing. 
 
h) Enuresis 
Enuresis means any involuntary loss of urine.  
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i) Nocturnal enuresis 
Nocturnal enuresis is loss of urine occurring during sleep. 
 
j) Continuous urinary incontinence 
Continuous urinary incontinence is continuous urinary leakage. 
 
k) Other types of urinary incontinence 
Other types of urinary incontinence may be situational, for example leakage during 
sexual intercourse, or giggle incontinence. 
 
l) Bladder sensation 
There are five types of bladder sensation, namely:  
• Normal: the individual is aware of bladder filling and increasing sensation up to 
a strong desire to void. 
• Increased: the individual feels an early and persistent desire to void. 
• Reduced: the individual is aware of bladder filling but does not feel a definite 
desire to void. 
• Absent: the individual reports no sensation of bladder filling or desire to void. 
• Non-specific: the individual reports no specific bladder sensation, but may 
perceive bladder filling as abdominal fullness, vegetative symptom, or 
spasticity. 
 
1.2.2 VOIDING SYMPTOMS 
The Standardisation Sub-committee of the ICS on the Standardisation of Terminology 
of Lower Urinary Tract Function defines voiding symptoms as symptoms experienced 
during the voiding phase and include the following (Abrams et al., 2002): 
 
 
5
a) Slow stream 
Slow stream is reduced urine flow rate and is usually compared with previous 
performance or with others. 
 
b) Splitting or spraying 
Splitting or spraying of the urine stream during voiding. 
 
c) Intermittent stream (Intermittency) 
Intermittent stream (Intermittency) is a term used when describing the urine flow, which 
stops and starts, on one or more occasions. 
 
d) Hesitancy 
Hesitancy is a term used when describing difficulty in initiating micturation resulting in a 
delay in the onset of voiding after the individual is ready to pass urine. 
 
e) Straining 
Straining to void occurs when there is muscular effort used to initiate, maintain or 
improve the urinary stream. 
 
f) Terminal dribbling 
Terminal dribbling is when a prolonged final part of micturation, when the flow has 
slowed to a trickle/dribble. 
 
1.2.3 POST MICTURATION SYMPTOMS 
According to the report by the Standardisation Sub-committee of the ICS on the 
Standardisation of Terminology of Lower Urinary Tract Function, post micturation 
symptoms are symptoms experienced immediately after micturation. They include the 
following (Abrams et al., 2002): 
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a) Feeling of incomplete emptying 
Feeling of incomplete emptying is a feeling that the bladder is still full even after 
passing urine. 
 
b) Post micturation dribble 
Post micturation dribble is a term used when an individual describes the involuntary 
loss of urine immediately after he or she has finished passing urine, usually after 
leaving the toilet in men, or after rising from the toilet in women. 
 
1.3 EPIDEMIOLOGY 
Voiding disorders in men have been extensively studied, but there is a paucity of 
studies assessing the voiding patterns and prevalence of urinary disorders, other than 
urinary incontinence in women (Yu et al., 1998; Swithinbank & Abrams, 2000; Takeda 
et al., 2003). Until recently, data on prevalence of FLUTS are scarce and limited by the 
non-standardisation of the definitions used. The reported prevalence of FLUTS varied 
from 12%-39% (Pinnock & Marshall, 1997; Yu et al., 1998; Moller et al., 2000a; Boyle 
et al., 2003a; Low et al., 2006). Prevalence of specific symptom prevalence was also 
reported to be high e.g., 61% for urgency, 43% for incomplete emptying (Swithinbank & 
Abrams, 2000). The wide variation in the prevalence rates can be explained by 
differences in definitions, target populations and study designs used (Groutz & Blaivas, 
2002; Moller et al., 2000a). Having a standardised and accepted international 
consensus definition on FLUTS will make future research and publication comparable 
(Low et al., 2006). 
 
As mentioned earlier, FLUTS is a very common condition and it adversely affects QOL. 
In an interview-based prevalence study conducted on 1686 women aged more than 18 
years old in September 1995 in Australia using validated International Prostate 
Symptom Score (IPSS), the prevalence of one or more troublesome LUTS was 39% for 
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women of all ages and 16% of the women were substantially dissatisfied with their 
urinary conditions (Pinnock & Marshall, 1997). The prevalence of LUTS occurring more 
than weekly was 27.8% for 2860 women aged 40 to 60 years using a self-
administered, validated and modified Bristol Female Lower Urinary Tract Symptoms 
(BFLUTS) questionnaire in one rural (Storstrøms) and one urban county (Copenhagen) 
in Denmark in June 1996 (Moller et al., 2000a). Specific symptom prevalence ranged 
from 6% to 61% from a postal-based prevalence survey in a group of 2075 women 
aged over 18 years registered with one general practice in Pill, a small village on the 
outskirts of Bristol (Swithinbank & Blaivas, 2000). These studies were conducted in 
western countries and epidemiologic data are not directly transferable from country to 
country because studies have shown that many factors, such as social status, cultural 
background, or accessibility of health care resources, contribute to LUTS-related health 
care-seeking behaviour (Takeda et al., 2003). The prevalence of FLUTS using IPSS >7 
in the self-administered prevalence study conducted in Taiwan and an interview-based 
prevalence study conducted in Korea were 21% and 19.9% respectively (Yu et al., 
1998; Boyle et al., 2003a). However, all these studies may not be directly comparable, 
because different methods were used to evaluate LUTS in women. In addition, of the 
five published studies, none had considered the treatment seeking behaviour and risk 
factors of patients with FLUTS. This is particularly important for health care policy 
providers in designing strategies and targeting it to the correct patient population (Low 
et al., 2006). 
 
1.4 ETIOLOGIES AND PATHOGENESIS 
LUTS occur when the lower urinary tract (LUT) fails to maintain its functions, namely, 
the storage and timely expulsion of urine (Groutz & Blaivas, 2002; Nordling, 2002). The 
etiology of LUTS is multi factorial and not fully understood (Moller et al., 2000b; Chaikin 
& Blaivas, 2001). Symptoms are poor indicators and present only a murky view of the 
underlying pathophysiology (Chaikin & Blaivas, 2001). Symptoms may be caused by a 
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finite number of underlying conditions that fall into two main categories: bladder 
abnormalities and urethral or sphincter abnormalities (Blaivas, 2000). 
 
1.4.1 BLADDER CONDITIONS CAUSING STORAGE SYMPTOMS 
1.4.1(a) DETRUSOR OVERACTIVITY 
Detrusor overactivity or involuntary detrusor contraction may be further subdivided into 
detrusor hyper-reflexia (involuntary detrusor contraction caused by neurological 
conditions) and detrusor instability (from non-neurological conditions) (Robinson, 1998; 
Blaivas, 2000; Nordling, 2002). Common causes of detrusor hyper-reflexia include 
stroke, multiple sclerosis, Parkinson’s disease, spinal cord injury, transverse myelitis 
and spinal bifida (Blaivas, 2000). Artibani (1997) suggested classifying the non-
neurogenic causes of detrusor instability into obstructive, congenital, behavioural-
psychosomatic, age-related, due to pelvic floor/urethral disorder, myogenic, 
hypersensitivity and mixed causes. Detrusor instability may have similar appearance 
and is associated with a variety of conditions that are assumed to be causative, e.g. 
urethral obstruction, infection, pelvic organ prolapse (POP), urethral diverticula and 
bladder cancer, but in most cases are idiopathic (Blaivas, 2000).  
 
1.4.1(b) SENSORY URGENCY 
Sensory urgency refers to an uncomfortable need to void which is not accompanied by 
(diagnosable) detrusor instability. It is most often idiopathic, but commonly seen in 
association with infections, bladder stones and cancer. When no cause is discerned, it 
is called painful bladder syndrome or interstitial cystitis (IC) (Blaivas, 2000). 
 
1.4.1(c) LOW BLADDER COMPLIANCE 
Low bladder compliance refers to an abnormal ‘stiffness’ of the bladder wall that is 
defined as the relationship between changes in the bladder volume and detrusor 
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pressure. Low bladder compliance may be functional (from increased detrusor tone), or 
anatomical (decreased viscoelasticity of the bladder wall). Common causes of low 
bladder compliance include neurogenic bladder, radiation, interstitial and tuberculous 
cystitis, and the long-term use of indwelling bladder catheters (Blaivas, 2000).  
 
1.4.2 SPHINCTER CONDITIONS CAUSING STORAGE SYMPTOMS 
Sphincter conditions causing storage symptoms are of two generic kinds, i.e. intrinsic 
sphincter deficiency (ISD) and urethral hypermobility (UH) (Blaivas, 2000). 
 
1.4.2(a) INTRINSIC SPHINCTER DEFICIENCY (ISD) 
ISD implies a weakness of the sphincter mechanism itself (Blaivas, 2000). Many 
factors are associated with the development of ISD. Age greater than 50 years 
(Horbach & Ostergard, 1994), prolonged menopausal status, sphincteric dysfunction 
resulting from the simple hysterectomy (Morgan et al., 2000), previous incontinence or 
prolapse surgery (Veronikis et al., 1997; Takahashi et al., 2000) were found to be 
associated with the development of ISD. Other causes include either congenital or 
acquired myelopathy (meningomyelocele or sacral cord lesion/injury), diabetic 
neuropathy, myeldysplasia, or Shy-Drager syndrome, which is a progressive neuronal 
degeneration within the brain and spinal cord (Betson et al., 2003) 
 
1.4.2(b) URETHRAL HYPERMOBILITY (UH) 
UH refers to abnormal movement of the urethra during increases in intra-abdominal 
pressure (Blaivas, 2000). 
 
1.4.3 BLADDER CONDITIONS CAUSING EMPTYING SYMPTOMS 
Bladder conditions causing emptying symptoms include impaired or absent detrusor 
contractility and bladder outlet obstruction (BOO) (Blaivas, 2000). 
 
10
1.4.3(a) IMPAIRED DETRUSOR CONTRACTILITY 
Impaired detrusor contractility may be caused by neurogenic disorders or detrusor 
decompensation. It may also be a learned voiding dysfunction or idiopathic. 
Neurogenic causes include spinal cord injury, spinal bifida, multiple sclerosis, diabetes 
mellitus and surgical insult such as radical hysterectomy and abdominoperineal 
resection of the rectum. Detrusor decompensation may occur after long-standing BOO 
(Blaivas, 2000). 
 
1.4.3(b) BLADDER OUTLET OBSTRUCTION (BOO) 
BOO may be anatomical or functional. Causes of the obstruction in the former include 
urethral stricture/fibrosis (usually after pelvic surgery or trauma), POP, urethral 
diverticula and tumour. Functional obstructions on the other hand are caused by 
detrusor sphincter dyssynergia, primary bladder neck obstruction and learned voiding 
dysfunction (dysfunctional voiding) (Blaivas, 2000). 
 
1.4.4 MYOGENIC BASIS CAUSING LUTS 
Myogenic is a hypothesised cause of detrusor instability, regardless of the etiology of 
the disease (Brading, 1997). Elbadawi and his colleagues (1993a, 1993b, 1993c, 
1993d) have proposed and established that the elderly have an abnormal number of 
intercellular connections used for communication between smooth muscle cells and 
could facilitate the generation of unplanned detrusor contractions. This ultrastructural 
study using electron microscopy was conducted in elderly patients with detrusor 
overactivity, associated or not associated with outflow obstruction or detrusor 
hypocontractility (Elbadawi et al., 1993a; Elbadawi et al., 1993b; Elbadawi et al., 1993c; 
Elbadawi et al., 1993d). Partial denervation of the detrusor may be responsible for 
altering the properties of the smooth muscle, leading to increased excitability and 
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increased ability of activity to spread between cells, resulting in coordinated myogenic 
contractions of the whole detrusor (Brading, 1997). 
 
1.5 NEUROLOGIC CONTROL OF LOWER URINARY TRACT (LUT) 
The LUT provides two functional modes of operation, the storage of urine over several 
hours and periodical micturation without residual urine (De Groat, 1997; Evans & 
Castleden, 1998; Andersson, 2002; Reitz et al., 2004; De Groat, 2006). The storage 
and periodic expulsion of urine is regulated by a neural control system in the brain and 
spinal cord. The neural control system coordinates the reciprocal activity of two 
functional units in the LUT: (a) a reservoir (the urinary bladder) and (b) an outlet 
(bladder neck, urethra and striated muscles of the urethral sphincter) (Benson, 1989; 
De Groat, 1997; Evans & Castleden, 1998; Andersson, 2002; Morrison et al., 2002; 
Reitz et al., 2004; De Groat, 2006). Control of the bladder and urethral outlet is 
dependent on three sets of peripheral nerves: sacral parasympathetic (pelvic nerves), 
thoracolumbar sympathetic (hypogastric nerves and sympathetic chain), and sacral 
somatic nerves (pudendal nerves). These nerves contain afferent as well as efferent 
pathways (De Groat, 1997; Evans & Castleden, 1998; Andersson, 2002; Morrison et 
al., 2002; Reitz et al., 2004; De Groat, 2006). The neural pathways controlling LUT 
function are organised as simple on-off switching circuits that maintain a reciprocal 
relationship between the urinary bladder and urethral outlet. The principal reflex 
components of these switching circuits are listed in Table 1.1 (De Groat, 1997; 
Morrison et al., 2002; De Groat, 2006) and illustrated in Figure 1.1 (Morrison et al., 
2002; De Groat, 2006). Normal storage of urine is dependent on 1) spinal reflex 
mechanisms that activate sympathetic and somatic pathways to the urethral outlet and 
2) tonic inhibitory systems in the brain that suppress the parasympathetic excitatory 
outflow to the urinary bladder. In contrast, voiding is mediated by inhibition of 
sympathetic-somatic pathways and activation of a spinobulbospinal parasympathetic 
reflex pathway passing through a coordination centre (the pontine micturation centre) 
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located in the brainstem (De Groat, 1997; Evans & Castleden, 1998; Morrison et al., 
2002; De Groat, 2006). Many neurotransmitters including acetylcholine (Ach), 
norepinephrine, dopamine, serotonin, excitatory and inhibitory amino acids, adenosine 
triphosphate (ATP), nitric oxide (NO) and neuropeptides are involved in the neural 
control of the LUT (De Groat, 2006). Please refer to Table 1.2 for the receptors for 
putative transmitters in the LUT (De Groat, 2006). 
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Table 1.1 Reflexes to the LUT (De Groat, 1997; Morrison et al., 2002; De Groat, 2006) 
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Figure 1.1 Diagram showing neural circuits controlling continence and micturation 
(Morrison et al., 2002; De Groat, 2006) 
 
 
 
 
 
 
 
 
 
 
 
 
 
15
Table 1.2 Receptors for putative transmitters in the LUT (De Groat, 2006) 
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1.5.1 CHOLINERGIC CONTROL OF LUT 
The sacral parasympathetic outflow provides the major excitatory input to the urinary 
bladder (De Groat, 2006). Parasympathetic nerve stimulation causes the release of 
Ach at postsynaptic parasympathetic receptor sites. Ach release produces muscarinic 
and nicotinic effects. However, the bladder has only muscarinic receptor sites. Thus, 
parasympathetic nerve stimulation causes contraction of the detrusor muscle and 
relaxation of the trigone via the muscarinic effect (Beck, 1989; Hoffman & Taylor, 
2001). The action of Ach is terminated by its breakdown by acetylcholinesterase (Beck, 
1989). Ach release may be inhibited by alpha2 receptor stimulation in the adrenergic 
control of the LUT (Hoffman & Taylor, 2001). Parasympathetic effect on LUT is 
modulated not only by adrenergic control but also by the effect of anticholinesterases, 
prostaglandins, histamine, calcium and potassium channel changes, purinergic nerves, 
and estrogen (Beck, 1989). The block of Ach effect on the detrusor muscle by atropine 
(a classical antimuscarinic drug) is less complete than the blockage of Ach by atropine 
elsewhere in the body (Brown & Taylor, 2001).  
 
1.5.2 ADRENERGIC CONTROL OF LUT 
The urethra and bladder have alpha- and beta-adrenergic receptor sites. Alpha-
receptor sites predominate in the urethra as compared to the detrusor muscle, and 
beta-receptor sites predominate in the detrusor as compared in the urethra. Beta1-
receptors occur mainly in cardiac muscle, and the LUT has only beta2-receptor. Beta-
receptor site stimulation produces relaxation of detrusor muscle. The alpha1- and 
alpha2- receptors are found in the LUT. Alpha1-receptors predominate at the 
postsynaptic receptor sites in the smooth muscle and stimulation causes smooth 
muscle contraction. Alpha2-receptor sites seem to modulate alpha1-stimulatory effect 
by inhibiting the release of transmitter substance (norepinephrine) and may also inhibit 
Ach release. The adrenergic transmitter substances are epinephrine and 
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norepinephrine. Epinephrine acts at beta-receptor sites and alpha1-receptor sites. 
Norepinephrine acts at alpha1- and beta1-receptor sites and has very little effect on 
beta2-receptor sites. Norepinephrine is less potent than epinephrine on alpha1-receptor 
sites and is as potent as epinephrine on beta1-receptor sites (in cardiac muscle) (Beck, 
1989). Epinephrine relaxes the detrusor muscle as a result of stimulation of beta-
receptor sites and causes contraction of the trigone and urethra as a result of alpha-
agonistic action (Hoffman & Taylor, 2001). Norepinephrine has little effect on the 
detrusor muscle (slight relaxant effect through weak beta2-stimulation), but it does not 
cause contraction of the urethra smooth muscles through alpha-stimulation (Beck, 
1989). 
 
1.5.3 PURINERGIC NERVE CONTROL OF LUT 
As mentioned earlier, parasympathetic nerve stimulation is not blocked by atropine and 
norepinephrine. This is because of the noncholinergic, nonadrenergic innervation of the 
bladder by purinergic nerves (Beck, 1989) which its excitatory transmission is mediated 
by ATP, acting on P2X purinergic receptors (Hoffman & Taylor, 2001). Andersson & 
Hedlund (2002) believed if activation via purinergic receptors is responsible not only for 
part of the bladder contractions, but also for the LUTS, it should be considered an 
important target for therapeutic interventions. 
 
1.6 RISK FACTORS 
Although studies have shown that FLUTS is highly prevalent in population survey and 
not only causes considerable loss financially but significantly reduces patients’ QOL, 
there have been a disproportionately low percentage of patients with FLUTS actively 
seeking treatment. It has been found that the major underlying reasons for those 
deferring treatment are lack of understanding of the disease progress and treatment 
options available. Thus, specifically quantified risk factors will be of particularly 
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importance for health care providers in providing treatment resources to the correct 
patient population. A properly structured dissemination of public education about 
FLUTS to the correct population may increase awareness among them and thus help 
in the early detection of patients with FLUTS as well as its prevention. 
 
Women with LUTS or urinary incontinence were found to be associated with many 
factors, such as age, childbirth, faecal difficulties, obstetric complications, obesity, 
pelvic surgery, medications, functional impairment, chronic diseases, menstrual cycle, 
race, family history, childhood enuresis and POP (Moller et al., 2000b; Minassian et al., 
2003; Holroyd & Straus, 2004; Jiang et al., 2004; Zhang et al., 2005). However, most of 
these studies were conducted in western women. Data of risk factors for women with 
LUTS or urinary incontinence in Asian women are lacking because of the scarcity of 
epidemiologic studies (Zhang et al., 2005). Besides, studies so far only included 
women of certain age groups such as menopausal women (Brown et al., 1999; Moller 
et al., 2000b; Muscatello et al., 2001; Parazzini et al., 2003; Dallosso et al., 2003; 
Manonai et al., 2004) and those middle-aged (Kuh et al., 1999; Teleman et al., 2004; 
Fitzgerald et al., 2006; Danforth et al., 2006), or special cohorts such as nuns 
(Buchsbaum et al., 2002). Moreover, when women of all ages were studied, the 
primary focus of research on women with LUTS was on overactive bladder (OAB) 
(Lapitan et al., 2001; Milleman et al., 2004) or urinary incontinence (Hagglund et al., 
1999; Peyrat et al., 2002; Grodstein et al., 2003; Kocak et al., 2005; Song et al., 2005; 
Song et al., 2006).  
 
1.7 DIAGNOSIS 
Ongoing controversy exists as to the extent of the necessary evaluation of women 
presenting with LUTS, but it is important to exclude pathology such as urinary tract 
infections in these women. Most would agree that a detailed history, a physical 
examination and a urine analysis are essential components of the initial evaluation of 
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patients with FLUTS (Abrams et al., 1988; Dorflinger & Monga, 2001; Rovner & Wein, 
2003). Beyond these assessments, however, there is no universally accepted guideline 
on the diagnosis. In certain patients, a urodynamic, endoscopic and/or radiographic 
evaluation may be indicated (Rovner & Wein, 2003). 
 
1.7.1 HISTORY 
Patient’s history begins with a detailed account of the precise nature of the patient’s 
reported LUTS (Blaivas, 2000; Gordon & Groutz, 2001), which should be characterised 
and quantified as accurately as possible. When one or more LUTS is present, the 
patient’s assessment of the relative severity of each symptom should be noted. 
Patient’s reported LUTS alone is not an accurate tool in the diagnosis and should not 
be used as the sole determinant of diagnosis or treatment (Bowen, 1989; Gordon & 
Groutz, 2001). 
 
The patient’s medical history should include questions relevant to neurological and 
congenital abnormalities as well as information on previous urinary tract infections and 
relevant surgery. The patient’s medical history should also include assessment of 
menstrual, sexual and bowel function, and obstetric history. Information must be 
obtained on medications with known or possible effects on the LUT (Abrams et al., 
1988; Bowen, 1989). Medications that are known to affect bladder and urethral function 
include anticholinergics, (e.g. probanthine, oxybutynin and tolterodine), tricyclic 
antidepressants (e.g. imipramine), narcotic analgesics, diuretics, alcohol, psychotropic 
medications, alpha agonists or antagonists, beta mimetics, calcium channel blockers 
and over-the-counter ‘cold-cure’ medicines that contain sympatomimetics (Bowen, 
1989; Robinson, 1998; Blaivas, 2000). Also, conditions which can produce symptoms 
mimicking LUTS should be ruled out. Diabetes, hypercalcemia, edema, congestive 
heart failure, excessive fluid intake, and volume overload may result in increased renal 
clearance with resultant symptoms of frequency, urgency, and even urge incontinence 
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(Robinson, 1998). Diabetes mellitus and hypothyroidism are endocrine abnormalities 
that may adversely affect bladder emptying. Viral infections such as herpes simplex or 
herpes zoster involving the sacral dermatomes produce a type of pelvic neuritis 
resulting in urinary retention. Other infections resulting in spinal cord myelitis such as 
postinfectious polyneuritis (Guillain-Barre syndrome) or transverse myellitis should be 
considered (Bowen, 1989). 
 
1.7.2 PHYSICAL EXAMINATION 
Physical examination should focus on detecting anatomic and neurologic abnormalities 
that contribute to the LUT dysfunction (Blaivas, 2000; Gordon & Groutz, 2001). A 
vaginal examination should be performed with the bladder both empty (to check the 
pelvic organs) and full (to check for incontinence and prolapse). Uterovaginal descent 
or prolapse with associated cystocele or a large cystocele alone may result in 
mechanical obstruction of the urethra and inefficient voiding. Cervical or uterine 
fibroids, large ovarian cysts or other masses, hypoestrogenism in menopausal women 
should be ruled out (Bowen, 1989). Assessment of perineal sensation, the perineal 
reflexes supplied by the sacral segments S2-S4, and anal sphincter tone and control 
can help to exclude neuropathy (Abrams et al., 1988; Bowen, 1989). 
 
1.7.3 URINE ANALYSIS 
Urinalysis and midstream specimen of urine should be undertaken to identify 
microscopic haematuria and infection. Gross and/or microscopic haematuria require 
separate evaluation to exclude tumours and stones. If urine analysis shows pyuria, the 
women should be treated empirically with antibiotics pending the results of culture and 
antibiotic sensitivities (Blaivas, 2000). Urinary infections can simulate any LUT 
pathologic condition, including detrusor instability or SUI. More than 60% of women 
with urodynamically proven stable bladders have temporary detrusor instability when 
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tested at the time of acute cystitis. Besides, more than 30% of women with a 
urodynamic diagnosis of stress incontinence made at a time of unsuspected cystitis 
were found to be continent when testing was repeated after infection was cleared. This 
is because Escherichia coli endotoxin has alpha-adrenergic blocking properties, 
decreasing urethral pressures (Bergman, 1989).  
 
1.7.4 MICTURATION DIARY 
A micturation diary is an important adjunct to the medical history that provides semi-
objective data about the patient’s micturation habits (Abrams et al., 1988; Blaivas, 
2000). The diary gives objective information on the number of voidings, the distribution 
of voidings between daytime and night-time and each voided volume (Abrams et al., 
1988). 
 
1.7.5 PAD TEST 
A pad test provides a useful semi-objective measurement of urine loss over a given 
period (Blaivas, 2000; Gordon & Groutz, 2001). In the simplest pad test, the patient 
changes his or her pads every 6 hour for one representative 24 hour period while he or 
she is taking pyridium (200 mg three times daily). The amount of staining on the pads 
is a rough estimate of the severity of the incontinence. Alternatively, the pads are 
weighed and the total weight (minus the weight of an unused pad) recorded in the 
patient’s record as an estimate of the volume of the urine loss (as 1 g ≈ 1 mL of urine); 
up to 8 g per day is considered normal (Blaivas, 2000). Oral pyridium is used to colour 
the urine, increasing the ability to discriminate urine from other body fluids such as 
sweat or vaginal discharge (Mutone & Valaitis, 2006). During the testing period, 
provocative maneuvers to elicit incontinence, such as physical activities to increase 
intra-abdominal pressure or putting the patient’s hands into running water may be 
included. Both short-term office (Peterson et al., 2005) and long-term home testing is 
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possible (Ryhammer et al., 1999). Pad testing may be valuable in situations where 
other objective tests are negative or the history is inconclusive. However, the limitation 
with this method is that a positive pad test does not specifically identify the cause of the 
incontinence e.g., stress or urge incontinence (Mutone & Valaitis, 2006). 
 
1.7.6 UROFLOWMETRY (‘FREE FLOW’) AND POST VOID RESIDUAL 
(PVR) URINE 
Uroflowmetry represents a simple initial test to assess the emptying phase of the LUT. 
Normal female voiding procedure is a bell-shaped curve on uroflowmetry. Voiding 
dysfunction may give rise to an intermittent or multiple peaked flows (Lose et al., 1998). 
Urinary flow rate (uroflowmetry) is a composite measure of the interaction between the 
pressure generated by the detrusor and the resistance offered by the urethra. Thus, a 
low flow rate may be caused either by BOO or impaired detrusor contractility (Blaivas, 
2000; Gordon & Groutz, 2001). Moreover, the flow may be normal in patients with BOO 
if they generate a high enough detrusor pressure to overcome the increased urethral 
resistance (Blaivas, 2000). To distinguish between obstruction and impaired detrusor 
contractility, detrusor pressure and flow must be measured simultaneously (Blaivas, 
2000; Gordon & Groutz, 2001).  
 
Post void residual (PVR) urine is defined as the volume of urine left in the bladder at 
the end of micturation (Abrams et al., 2002). PVR is a useful measure of the emptying 
function of the bladder (Blaivas, 2000). Most clinicians would consider a PVR of up to 
50 mL as normal (Bowen, 1989; Robinson, 1998; Blaivas, 2000), and a residual of over 
200 mL as problematic (Robinson, 1998). A large PVR may be caused by either 
urethral obstruction or impaired detrusor contractility (Bowen, 1989; Blaivas, 2000). 
The presence of persistently increased PVR urine warrants clinical attention (Robinson, 
1998) and further urodynamic investigation is usually necessary (Bowen, 1989). 
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1.7.7 URODYNAMIC EVALUATION 
Urodynamic investigation was developed as an extension of patient history and 
physical examination in order to reveal the pathophysiology of a patient’s complaints 
(Gordon & Groutz, 2001; Heesakkers & Vriesema, 2005). Urodynamic investigation 
tries to copy the function of the LUT, storage and expulsion, in a controlled and 
measurable setting (Heesakkers & Vriesema, 2005). As such, results of the 
urodynamic studies should clearly reflect the patient’s symptoms and signs (Walters, 
1989). A complete urodynamic investigation is not necessary in all symptomatic 
patients (Walters, 1989; Bergman, 1989). According to ICS (Abrams et al., 2002), there 
are two principal methods of urodynamic investigation, namely, conventional 
urodynamic studies and ambulatory urodynamic studies. Conventional urodynamic 
studies normally take place in the urodynamic laboratory and usually involve artificial 
bladder filing. Artificial bladder filling is defined as filling the bladder, via a catheter, with 
a specified liquid at a specified rate. Ambulatory urodynamic studies are defined as a 
functional test of the LUT, utilising natural filling, and reproducing the subject’s every 
day activities. Natural filling means that the bladder is filled by the production of urine 
rather than by an artificial medium. A urodynamic investigation consists of cystometry 
and pressure flow study. 
 
1.7.7(a) CYSTOMETRY 
Cystometry is the method by which the pressure/volume relationship of the bladder is 
measured during bladder filling. The filling phase starts when filling commences and 
ends when the patient and urodynamicist decide that ‘permission to void’ has been 
given (Abrams et al., 2002). Cystometry is used to assess bladder sensation (Table 
1.3), activity (Table 1.4), capacity (Table 1.5) and compliance (Table 1.6) during 
storage phase (Walters, 1989; Blaivas, 2000; Abrams et al., 2002). Also, cystometry is 
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used to describe urethral function during storage phase (Table 1.7) as competent or 
incompetent (Abrams et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
